ArticleNature communications2022
Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00375674 (Sunitinib Treatment Of Renal Adjuvant Cancer), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent Rcc
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Updates on Clinical Trials and Molecular Characteristics of Locally Advanced and Oligometastatic Renal Cell Carcinoma.International journal of molecular sciences · 2026Review
- Tumor cell FAP orchestrates EMT and immune suppression in aggressive localized ccRCC.Theranostics · 2026Article
- International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma.Frontiers in oncology · 2026Article
- Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma.BJUI compass · 2025Article
- Validation of a 15-Gene Prognostic Signature in Metastatic Clear Cell Renal Cell Carcinoma.JCO precision oncology · 2025Article
- Differences in mutations across tumour sizes in clear-cell renal cell carcinoma.BJU international · 2025Article
- Article
- Bioinformatics in urology - molecular characterization of pathophysiology and response to treatment.Nature reviews. Urology · 2024Review
- The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma.Human vaccines & immunotherapeutics · 2023Review
- Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
Abstract
Multigene assays can provide insight into key biological processes and prognostic information to guide development and selection of adjuvant cancer therapy. We report a comprehensive genomic and transcriptomic analysis of tumor samples from 171 patients at high risk for recurrent renal cell carcinoma post nephrectomy from the S-TRAC trial (NCT00375674). We identify gene expression signatures, including STRAC11 (derived from the sunitinib-treated population). The overlap in key elements captured in these gene expression signatures, which include genes representative of the tumor stroma microenvironment, regulatory T cell, and myeloid cells, suggests they are likely to be both prognostic and predictive of the anti-angiogenic effect in the adjuvant setting. These signatures also point to the identification of potential therapeutic targets for development in adjuvant renal cell carcinoma, such as MERTK and TDO2. Finally, our findings suggest that while anti-angiogenic adjuvant therapy might be important, it may not be sufficient to prevent recurrence and that other factors such as immune response and tumor environment may be of greater importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.